Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany

Tino Prell^{1

2}, Frank Siebecker³, Michael Lorrain⁴, Carsten Eggers⁵, Stefan Lorenzl^{6

7}, Jochen Klucken^{8

9

10}, Tobias Warnecke¹¹, Carsten Buhmann¹², Lars Tönges¹³, Reinhard Ehret¹⁴, Ingmar Wellach^{15

16}, Martin Wolz¹⁷

Affiliations

¹ Department of Neurology, Jena University Hospital, 07740 Jena, Germany.
² Center for Healthy Ageing, Jena University Hospital, 07740 Jena, Germany.
³ Praxis Neurologie, 48291 Telgte, Germany.
⁴ Nervenarztpraxis Gerresheim-Pempelfort, 40477 Düsseldorf, Germany.
⁵ Department of Neurology, University Hospital Marburg, 35037 Marburg, Germany.
⁶ Professorship for Palliative Care, Paracelsus Medical University, 5020 Salzburg, Austria, Department of Palliative Medicine, Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
⁷ Department of Neurology, Klinikum Agatharied, 83734 Hausham, Germany.
⁸ Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
⁹ Medical Valley-Digital Health Application Center GmbH, 96047, Bamberg, Germany.
¹⁰ Fraunhofer Institute for Integrated Circuits, 91058, Erlangen, Germany.
¹¹ Department of Neurology, University of Muenster, 48149 Münster, Germany.
¹² Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
¹³ Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.
¹⁴ Praxis Neurologie, 12163 Berlin, Germany.
¹⁵ Office for Neurology and Psychiatry Hamburg Walddörfer, Wiesenkamp 22 c, 22359 Hamburg, Germany.
¹⁶ Department of Neurology, Ev. Amalie, Sieveking Hospital, 22359 Hamburg, Germany.
¹⁷ Department of Neurology, Elblandklinikum Meißen, 01662 Meißen, Germany.

PMID: 32414071
PMCID: PMC7290836
DOI: 10.3390/jcm9051455

Review

Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany

Tino Prell et al. J Clin Med. 2020.

. 2020 May 13;9(5):1455.

doi: 10.3390/jcm9051455.

Authors

Affiliations

¹ Department of Neurology, Jena University Hospital, 07740 Jena, Germany.
² Center for Healthy Ageing, Jena University Hospital, 07740 Jena, Germany.
³ Praxis Neurologie, 48291 Telgte, Germany.
⁴ Nervenarztpraxis Gerresheim-Pempelfort, 40477 Düsseldorf, Germany.
⁵ Department of Neurology, University Hospital Marburg, 35037 Marburg, Germany.
⁶ Professorship for Palliative Care, Paracelsus Medical University, 5020 Salzburg, Austria, Department of Palliative Medicine, Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
⁷ Department of Neurology, Klinikum Agatharied, 83734 Hausham, Germany.
⁸ Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
⁹ Medical Valley-Digital Health Application Center GmbH, 96047, Bamberg, Germany.
¹⁰ Fraunhofer Institute for Integrated Circuits, 91058, Erlangen, Germany.
¹¹ Department of Neurology, University of Muenster, 48149 Münster, Germany.
¹² Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
¹³ Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.
¹⁴ Praxis Neurologie, 12163 Berlin, Germany.
¹⁵ Office for Neurology and Psychiatry Hamburg Walddörfer, Wiesenkamp 22 c, 22359 Hamburg, Germany.
¹⁶ Department of Neurology, Ev. Amalie, Sieveking Hospital, 22359 Hamburg, Germany.
¹⁷ Department of Neurology, Elblandklinikum Meißen, 01662 Meißen, Germany.

PMID: 32414071
PMCID: PMC7290836
DOI: 10.3390/jcm9051455

Abstract

Although our understanding of Parkinson´s disease (PD) has improved and effective treatments are available, caring for people with PD remains a challenge. The large heterogeneity in terms of motor symptoms, nonmotor symptoms, and disease progression makes tailored individual therapy and individual timing of treatment necessary. On the other hand, only limited resources are available for a growing number of patients, and the high quality of treatment cannot be guaranteed across the board. At this point, networks can help to make better use of resources and improve care. The working group PD Networks and Integrated Care, part of the German Parkinson Society, is entrusted to convene clinicians, therapists, nurses, researchers, and patients to promote the development of PD networks. This article summarizes the work carried out by the working group PD Networks and Integrated Care in the development of standards of network care for patients with PD in Germany.

Keywords: advanced care planning; day clinic; multimodal complex treatment; networks; telemedicine.

PubMed Disclaimer

Conflict of interest statement

Tino Prell has received BMBF research grant, and honoraria for presentations/lectures AbbVie GmbH, UCB Pharma GmbH, Desitin GmbH, Licher MT GmbH, and Bayer AG Deutschland. Frank Siebecker reports no conflict of interest. Michael Lorrain has received honoraria and compensation for consultancy and lecturing from Abbvie, Afi, Bayer, Bial, Biogen, Desitin, Merck, Nordrheinische Akademie, Teva, Ucb, and Zambon. Carsten Eggers received payments as a consultant for Abbvie Inc. CE received honoraria as a speaker from Abbvie Inc., Daiichi Sankyo Inc., Bayer Vital Inc. CE received payments as a consultant for Abbvie Inc. and Philyra Inc. Stefan Lorenzl reports no conflict of interest. Jochen Klucken reports institutional research grants from Bavarian Research Foundation; Emerging Field Initiative, FAU, EIT-Health, EIT-Digital, EU (H2020), German Research Foundation (DFG), and BMBF, and industry-sponsored institutional IITs and grants from Teva GmbH, Licher MT GmbH, Astrum IT GmbH, and Alpha-Telemed AG. He is coemployed by the University Hospital Erlangen, Germany, Fraunhofer Institute for Integrated Circuits e.V., Germany, and the Medical Valley Digital Health Application Center GmbH, Bamberg, Germany. He works on advisory boards in the field of healthcare technologies and digital health of different associations of medical professionals, industries, and political authorities. He holds shares of Portabiles HealthCare Technologies GmbH, Portabiles GmbH, Alpha-Telemed AG, and received compensation and honoraria from serving on scientific advisory boards for LicherMT GmbH, Abbvie GmbH, UCB Pharma GmbH; he has lectured at UCB Pharma GmbH, TEVA Pharma GmbH, Licher MT GmbH, Desitin GmbH, Abbvie GmbH, Solvay Pharmaceuticals, Bial Deutschland GmbH; Celgene GmbH, Lundbeck-Foundation. Dr. Klucken has a patent related to gait assessments pending. Tobias Warnecke has received honoraria from AbbVie (lecture fees, consultant). AbbVie acts as coinitiator of the Parkinsonnetwork Muensterland+ (PNM+) and is cocontractor of the University Hospital of Muenster. Carsten Buhmann has received fees as speaker and/or advisor from Abbvie, Bial, Desitin, Grünenthal, Licher, Novartis, TAD Pharma, UCB, and Zambon. Lars Tönges has received travel funding and/or speaker honoraria from Abbvie, Bayer, Bial, Desitin, GE, UCB, and Zambon, and consulted for Abbvie, Bayer, Bial, Desitin, UCB, and Zambon, in the last 3 years. Reinhard Ehret reports no conflict of interests. Ingmar Wellach has received honoraria an compensation for consultancy and lecturing from AbbVie GmbH, UCB Pharma GmbH, Desitin GmbH, Bial Deutschland GmbH, Zambon Deutschland GmbH, Fagron GmbH & Co. KG, Grünenthal GmbH, and Bayer AG Deutschland. Martin Wolz has received honoraria for presentations/lectures from Zambon, Valeant, Desitin, TEVA, UCB Pharma, Abbvie, Bial, Licher, and Daiichi Sankyo.

Figures

**Figure 1**
Schematized representation of common players and structures in a local supply network.

See this image and copyright information in PMC

References

1. Ascherio A., Schwarzschild M.A. The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol. 2016;15:1257–1272. doi: 10.1016/S1474-4422(16)30230-7. - DOI - PubMed
1. Pfeiffer R.F. Nonmotor symptoms in Parkinson’s disease. Park. Relat. Disord. 2016;22(Suppl. 1):S119–S122. doi: 10.1016/j.parkreldis.2015.09.004. - DOI - PubMed
1. Ri Richter D., Bartig D., Muhlack S., Hartelt E., Scherbaum R., Katsanos A.H., Müller T., Jost W.H., Ebersbach G., Gold R., et al. Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers. Cells. 2019;8:151. doi: 10.3390/cells8020151. - DOI - PMC - PubMed
1. Tonges L., Bartig D., Muhlack S., Jost W., Gold R., Krogias C. Characteristics and dynamics of inpatient treatment of patients with Parkinson’s disease in Germany: Analysis of 1.5 million patient cases from 2010 to 2015. Der Nervenarzt. 2019;90:167–174. - PubMed
1. Binder S.G.S., Woitalla D., Müller T., Wellach I., Klucken J., Eggers C., Liersch S., Amelung V. Patients’ Perspective on Provided Health Services in Parkinson’s Disease in Germany–a Cross-Sectional Survey. Akt Neurol. 2018;45:703–713. doi: 10.1055/a-0624-1671. - DOI

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany

Affiliations

Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

LinkOut - more resources

Full Text Sources